Research Interests
Coming from a background of clinical research in haematology and oncology and having been board certified in transfusion medicine, my interest is in the field of using nanocarriers for the treatment of malignant disease and on a broader range in immunological control of diseases and cellular therapies. Hallmarks of the development of nanocarrier systems were liposomes like Doxil® and iron oxide nanoparticles like Resovist®. Since then the research for nanocarriers has been hampered by a lack of understanding of the confounding factors leading to drug delivery by nanocarriers. Being able to understand when the targeting of nanocarriers could work and when the targeting cannot work is a major goal or our research. We, therefore, have been investigating the deteriorating effect of adsorbed proteins on nanocarriers. Our future focus will be on transforming our in vitro knowledge into in vivo approaches and demonstrate the level of effectiveness of targeting and its biological impact.